NeuroOne Medical Technologies Expands Executive Leadership with Promotion of Emily Johns to Chief Administrative Officer

NeuroOne Medical Technologies Corporation has announced the promotion of Emily Johns to the expanded role of Chief Administrative Officer and General Counsel. This strategic move comes as the medical technology company continues to develop innovative solutions for neurological disorders. Johns, who joined NeuroOne earlier this year as General Counsel, will now oversee all human resources, compliance, security and risk management functions in addition to leading the company's legal strategy.

Dave Rosa, President and CEO of NeuroOne, emphasized the significance of this promotion, stating that Johns has already made impactful contributions to the organization and the future growth of the business since joining the company. The expanded role reflects the company's confidence in her ability to help scale operations as NeuroOne advances its mission to improve surgical care options for patients suffering from conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. Rosa expressed optimism about her future contributions to the company's growth trajectory.

Johns brings substantial experience to her expanded responsibilities, having previously served as a partner at Honigman LLP where she represented numerous companies in the life sciences industry. Her background includes representing NeuroOne on all transactional work since 2017, providing her with deep institutional knowledge of the company's operations and strategic direction. Prior to her tenure at Honigman, Johns began her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and merger and acquisition transactions.

In her statement regarding the promotion, Johns expressed honor in stepping into the expanded role and commitment to building on the strong foundation established by the NeuroOne team. She highlighted her focus on strengthening operations and infrastructure to help bring what the company describes as life-changing technologies to more patients. This promotion occurs as NeuroOne continues to commercialize minimally invasive and high-definition solutions for EEG recording, stimulation and ablation procedures that aim to improve patient outcomes while reducing procedural costs.

The company's technology portfolio addresses significant unmet needs in neurological care, with potential applications extending to other conditions such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence integration. For additional information about the company's developments, visit https://www.nmtc1.com. This leadership expansion signals NeuroOne's commitment to strengthening its operational capabilities as it progresses toward bringing innovative neurological treatments to market and potentially transforming care for patients with challenging neurological conditions.